Dare Bioscience receives $3.6M in additional grant funding

Dare Bioscience (DARE) received an approximately $3.6 million payment under an existing grant agreement with the Gates Foundation. This new tranche will primarily support ongoing activities to aid in the identification and development of a novel non-hormonal intravaginal contraceptive, suitable for and acceptable to women in low- and middle-income country settings who need or would prefer to use such a product to avoid an unplanned pregnancy. This payment represents the next tranche under the up to approximately $10.7 million grant agreement originally announced in November 2024 and reflects Dare’s continued achievement of key development and reporting milestones.